DNLI
Price
$12.70
Change
+$0.20 (+1.60%)
Updated
Apr 11 closing price
Capitalization
1.84B
31 days until earnings call
RNA
Price
$25.58
Change
+$1.47 (+6.10%)
Updated
Apr 11 closing price
Capitalization
3.08B
31 days until earnings call
Ad is loading...

DNLI vs RNA

Header iconDNLI vs RNA Comparison
Open Charts DNLI vs RNABanner chart's image
Denali Therapeutics
Price$12.70
Change+$0.20 (+1.60%)
Volume$1.63M
Capitalization1.84B
Avidity Biosciences
Price$25.58
Change+$1.47 (+6.10%)
Volume$1.55M
Capitalization3.08B
DNLI vs RNA Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. RNA commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and RNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (DNLI: $12.70 vs. RNA: $25.58)
Brand notoriety: DNLI and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 119% vs. RNA: 99%
Market capitalization -- DNLI: $1.84B vs. RNA: $3.08B
DNLI [@Biotechnology] is valued at $1.84B. RNA’s [@Biotechnology] market capitalization is $3.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, RNA is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while RNA’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • RNA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than RNA.

Price Growth

DNLI (@Biotechnology) experienced а +7.81% price change this week, while RNA (@Biotechnology) price change was -3.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

RNA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($3.08B) has a higher market cap than DNLI($1.84B). RNA YTD gains are higher at: -12.036 vs. DNLI (-37.684). RNA has higher annual earnings (EBITDA): -376.16M vs. DNLI (-492.89M). RNA has more cash in the bank: 1.5B vs. DNLI (832M). RNA has less debt than DNLI: RNA (6.8M) vs DNLI (48.7M). RNA has higher revenues than DNLI: RNA (10.9M) vs DNLI (0).
DNLIRNADNLI / RNA
Capitalization1.84B3.08B60%
EBITDA-492.89M-376.16M131%
Gain YTD-37.684-12.036313%
P/E RatioN/AN/A-
Revenue010.9M-
Total Cash832M1.5B55%
Total Debt48.7M6.8M716%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
38
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRNA
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 20 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNPGX58.501.03
+1.79%
American Funds New Perspective R6
EAERX18.76N/A
N/A
Eaton Vance Stock A
BASAX17.85N/A
N/A
Brown Advisory Small-Cap Growth Adv
IHOVX19.10N/A
N/A
Hartford International Opportunities R6
MIDFX46.99N/A
N/A
Marsico Midcap Growth Focus Instl

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.60%
RCKT - DNLI
60%
Loosely correlated
+6.68%
BEAM - DNLI
58%
Loosely correlated
+5.74%
NTLA - DNLI
56%
Loosely correlated
+9.45%
CRSP - DNLI
54%
Loosely correlated
+14.71%
RGNX - DNLI
54%
Loosely correlated
+8.87%
More